PALO ALTO, Calif., July 28, 2021 /PRNewswire/ -- Landing
AI™ announced today a software licensing agreement
with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to
incorporate LandingLens™ into Ligand's
OmniAb® and xPloration™
antibody discovery platforms. LandingLens™ is a
software platform that provides an end-to-end workflow to build,
iterate and operationalize AI-powered visual inspection
solutions.
The new AI-driven tools further improve Ligand's high-throughput
single B cell screening accuracy and throughput in a variety of
complex biological assays, potentially increasing the yield of
antibodies with desirable properties in even less time.
"Landing AI, under the leadership of world-renowned AI pioneer
Andrew Ng, is a proven and trusted
partner in empowering their customers to realize the business value
of computer vision," says Bob Chen,
Ph.D., Director, Systems Engineering with Ligand Pharmaceuticals.
"We selected Landing AI because of the company's unique
data-centric approach that puts getting high-quality data at the
heart of AI development. Notably, the LandingLens™
software platform provides a host of specifically designed data
preparation tools and capabilities that allow us to generate
accurate and consistent datasets that we can iterate over time to
continuously improve our existing AI systems."
"AI and deep learning have emerged as powerful technologies to
enable a variety of vision-based applications. We are excited to
enter into this partnership with Ligand Pharmaceuticals and are
committed to offering the best tools to help our customers unlock
the promise of AI," said John
Reuter, Vice President of Sales at Landing AI.
About OmniAb®
The OmniAb
antibody discovery platform provides Ligand's biopharmaceutical
industry partners access to the world's most advanced antibody
repertoires and screening technologies to enable unparalleled
discovery of next-generation therapeutics. At the heart of the
OmniAb platform is the Biological Intelligence™ (BI)
of Ligand's proprietary transgenic animals including OmniRat,
OmniChicken and OmniMouse, each capable of generating high-quality
fully human antibodies that have been optimized naturally through
in vivo affinity maturation. OmniFlic (transgenic rat) and OmniClic
(transgenic chicken) address industry needs for bispecific antibody
applications though a common light chain approach, and OmniTaur
features unique structural attributes of cow antibodies for complex
targets. OmniAb animals comprise the most diverse host systems
available in the industry and they are optimally leveraged through
AI-enhanced antigen design and immunization methods, paired with
high-throughput microfluidic-based single B cell screening and deep
computational analysis of next-generation sequencing datasets to
identify fully human antibodies with superior performance and
developability characteristics. The OmniAb suite of technologies
and differentiating AI and BI features are combined to offer a
highly efficient and customizable end-to-end solution for the
growing antibody discovery needs of the global biopharmaceutical
industry.
About Ligand Pharmaceuticals
Ligand is a
revenue-generating biopharmaceutical company focused on developing
or acquiring technologies that help pharmaceutical companies
discover and develop medicines. Ligand's business model creates
value for stockholders by providing a diversified portfolio of
biotech and pharmaceutical product revenue streams that are
supported by an efficient and low corporate cost structure.
Ligand's goal is to offer investors an opportunity to participate
in the promise of the biotech industry in a profitable, diversified
and lower-risk business than a typical biotech company. Ligand's
business model is based on doing what Ligand does best: drug
discovery, early-stage drug development, product reformulation and
partnering. Ligand partners with other pharmaceutical companies to
leverage what they do best (late-stage development, regulatory
management and commercialization) to ultimately generate our
revenue. Ligand's OmniAb® technology platform is a
patent-protected technology stack used in the discovery of fully
human mono- and bispecific therapeutic antibodies. The Captisol
platform technology is a patent-protected, chemically modified
cyclodextrin with a structure designed to optimize the solubility
and stability of drugs. Ligand's Pelican® Expression
Technology is a robust, validated, cost-effective and scalable
approach to recombinant protein production, and is especially
well-suited for complex, large-scale protein production that cannot
be made by more traditional systems. Ligand has established
multiple alliances, licenses and other business relationships with
the world's leading pharmaceutical companies including Amgen,
Merck, Pfizer, Sanofi, Janssen, Takeda, Gilead Sciences and Baxter
International.
About Landing AI
Landing AI™ empowers
customers to realize the business and operational value of computer
vision using enablement tools. The company's flagship product is
LandingLens™, an enterprise MLOps platform that offers
end-to-end workflow to build, iterate and operationalize AI powered
visual inspection solutions. With data quality being a key to the
success of production AI systems, LandingLens™ is
equipped with a host of specially designed data preparation tools
and workflows that help users achieve optimal data accuracy and
consistency. Founded by Dr. Andrew
Ng, co-founder of Coursera, former chief scientist of Baidu,
and founding lead of Google Brain and guided by a data-centric AI
approach, Landing AI is uniquely positioned to help companies
successfully move their AI projects from proof-of-concept to
full-scale production.
Contact:
Press@landing.ai
View original
content:https://www.prnewswire.com/news-releases/landing-ais-landinglens-visual-inspection-software-platform-selected-by-ligand-pharmaceuticals-to-further-empower-the-omniab-and-xploration-antibody-discovery-platforms-301343587.html
SOURCE landing.ai